Form D · Pharmaceuticals
GYRE THERAPEUTICS, INC.
San Diego, CA · CIK 0001124105
Offering snapshot reported Nov 13, 2023 · SEC filing
- Reported sold
- $5M Offering amount: $5M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 30, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 13, 2023 | Initial | $5,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-497103
Source: Form D, filed Nov 13, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Gordon G. Carmichael | Director |
| Ruoyu Chen | Executive |
| Thomas Eastling | Director |
| Ying Luo | Director |
| Songjiang Ma | Director, Executive |
| Usman Nassim | Director |
| Renate Parry | Director |
| Charles Wu | Director, Executive |
| Han Ying | Director |
| Weiguo Yu | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
12770 High Bluff Drive Suite 150
San Diego, CA, 92130
San Diego, CA, 92130